The Company's API site at Changzhou underwent a GMP surveillance inspection by the FDA that began on March 4. Covering 21 FDA ...

With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is ... production facility in Singapore, which is expected to commence early operations in 2027. WuXi AppTec’s business is ...

China's WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum. The contract development and ...

Shares in WuXi Biologics and WuXi AppTec have tracked up after the BIOSECURE ... are able to deliver to healthcare systems. The ISPE Singapore Affiliate Conference & Exhibition is one of the ...

Our forward-looking statements do not constitute any profit forecast by our management nor a undertaking by WuXi AppTec Co., Ltd. ("WuXi AppTec" or the "Company") to our investors. ACCORDINGLY ...

WuXi AppTec continued to build its U.S. (Middletown, DE) site, which is expected to commence operations by the end of 2026. In May 2024, the company announced the groundbreaking of Singapore R&D ...

SHANGHAI, March 31, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides ... sites are critical manufacturing bases of WuXi STA, the company's small molecule CDMO platform, and WuXi ...

SHANGHAI, March 31, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio ... The Changzhou and Taixing sites are critical manufacturing bases of WuXi STA, the company's ...